Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

Inclisiran is a double-stranded small interfering RNA that suppresses proprotein convertase subtilisin-kexin type 9 (PCSK9) translation in the liver, leading to sustained reductions in low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoproteins with twice-yearly dosing. The purpos...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the American College of Cardiology Vol. 77; no. 9; p. 1182
Main Authors:	Wright, R Scott, Ray, Kausik K, Raal, Frederick J, Kallend, David G, Jaros, Mark, Koenig, Wolfgang, Leiter, Lawrence A, Landmesser, Ulf, Schwartz, Gregory G, Friedman, Andrew, Wijngaard, Peter L J, Garcia Conde, Lorena, Kastelein, John J P
Format:	Journal Article
Language:	English
Published:	United States 09.03.2021
Subjects:	Aged Atherosclerosis - blood Atherosclerosis - diagnosis Atherosclerosis - drug therapy Cholesterol, LDL - antagonists & inhibitors Cholesterol, LDL - blood Clinical Trials, Phase III as Topic - methods Female Humans Hyperlipoproteinemia Type II - blood Hyperlipoproteinemia Type II - diagnosis Hyperlipoproteinemia Type II - drug therapy Male Middle Aged RNA, Small Interfering - pharmacology RNA, Small Interfering - therapeutic use inclisiran lipid-lowering therapy RNA silencing low-density lipoprotein cholesterol ASVCD
ISSN:	1558-3597, 1558-3597
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!